IPP Bureau
Alcon launches Hydrus Microstent in India to transform glaucoma care
By IPP Bureau - March 11, 2026
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Roche reports Phase III persevERA breast cancer trial results
By IPP Bureau - March 11, 2026
Giredestrant shows promise despite missing primary goal
Cirena licenses breakthrough RNA synthesis technology from CU Boulder
By IPP Bureau - March 11, 2026
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
Pfizer’s experimental atopic dermatitis drug shows strong Phase 2 results
By IPP Bureau - March 11, 2026
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Roche shareholders back full slate of proposals, approve record dividend increase
By IPP Bureau - March 11, 2026
Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes
Codis expands UK manufacturing with groundbreaking spray dryer
By IPP Bureau - March 10, 2026
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
UK pushes space-made medicines from orbit to patients with new support package
By IPP Bureau - March 10, 2026
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Lifecore Biomedical teams up with Indomo to advance at-home acne therapy
By IPP Bureau - March 10, 2026
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development
By IPP Bureau - March 10, 2026
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Frontage Laboratories expands China presence with Teddy Lab acquisition
By IPP Bureau - March 10, 2026
Mosaic Clinical Technologies’ AI breakthrough earns FDA “Breakthrough Device” designation
By IPP Bureau - March 10, 2026
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
GAIA and Daiichi Sankyo Europe join forces to launch groundbreaking digital therapeutic for heart health
By IPP Bureau - March 10, 2026
Germany will be the first launch market
KIMS Hospitals makes bold entry into Bengaluru with two new super-speciality units
By IPP Bureau - March 10, 2026
The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management
Novo Nordisk strikes deal with Hims & Hers, expands access to Ozempic & Wegovy in US
By IPP Bureau - March 10, 2026
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
